Pancytopenia due to linezolid treatment

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology
• Hematology

Background:

• Antibiotic resistance is a growing concern in pediatric severe infections, particularly with Gram-positive bacteria like Enterococcus.
• Linezolid is a newer antibiotic effective against Gram-positive organisms, including resistant strains.
• Enterococcal infections, especially vancomycin-resistant strains, pose significant treatment challenges in pediatric patients.

Observation:

• A 10-month-old female with hydrocephalus and meningomyelocele developed vancomycin-resistant Enterococcus faecium and extended-spectrum beta-lactamase positive Escherichia coli meningitis.
• The patient was treated with linezolid and meropenem, showing initial improvement in cerebrospinal fluid findings.
• Bone marrow suppression was observed during the second week of linezolid therapy.

Findings:

• Linezolid treatment led to reversible bone marrow suppression in a pediatric patient.
• Cerebrospinal fluid infection markers improved with linezolid and meropenem.
• Discontinuation of linezolid resulted in the normalization of blood cell counts.

Implications:

• Linezolid, while effective for Gram-positive infections, carries a risk of reversible bone marrow suppression in pediatric patients.
• Careful monitoring of hematological parameters is crucial during linezolid therapy in children.
• This case underscores the need for cautious use and vigilant monitoring of newer antibiotics in pediatric populations.